Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype

被引:7
|
作者
Liu, Yu [1 ]
Chen, Yufei [1 ]
Liu, Yajun [2 ]
Li, Mengya [1 ]
Zhang, Yu [1 ]
Shi, Luyao [1 ]
Yang, Lu [1 ]
Li, Tao [1 ]
Li, Yafei [1 ]
Jiang, Zhongxing [1 ]
Liu, Yanfang [1 ]
Wang, Chong [1 ]
Wang, Shujuan [1 ]
机构
[1] Zhengzhou Univ, Dept Hematol, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China
[2] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Orthopaed, Providence, RI USA
基金
中国国家自然科学基金;
关键词
Acute myeloid leukemia; Prognosis; SMIM3; Cell proliferation; Cell cycle; PI3K-AKT; VEL BLOOD-GROUP; GAMMA-SUBUNIT; CELL; PROTEIN; SIGNATURE; SURVIVAL; MUTATION; ARREST; IMPACT; AML;
D O I
10.1186/s12967-022-03831-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Acute myeloid leukemia (AML) patients with normal karyotype (NK-AML) have significant variabilities in outcomes. The European Leukemia Net stratification system and some prognostic models have been used to evaluate risk stratification. However, these common standards still have some limitations. The biological functions and mechanisms of Small Integral Membrane Protein 3 (SMIM3) have seldomly been investigated. To this date, the prognostic value of SMIM3 in AML has not been reported. This study aimed to explore the clinical significance, biological effects and molecular mechanisms of SMIM3 in AML. Methods: RT-qPCR was applied to detect the expression level of SMIM3 in bone marrow specimens from 236 newly diagnosed adult AML patients and 23 healthy volunteers. AML cell lines, Kasumi-1 and THP-1, were used for lentiviral transfection. CCK8 and colony formation assays were used to detect cell proliferation. Cell cycle and apoptosis were analyzed by flow cytometry. Western blot was performed to explore relevant signaling pathways. The biological functions of SMIM3 in vivo were validated by xenograft tumor mouse model. Survival rate was evaluated by Log-Rank test and Kaplan-Meier. Cox regression model was used to analyze multivariate analysis. The correlations between SMIM3 and drug resistance were also explored. Results: Through multiple datasets and our clinical group, SMIM3 was shown to be significantly upregulated in adult AML compared to healthy subjects. SMIM3 overexpression conferred a worse prognosis and was identified as an independent prognostic factor in 95 adult NK-AML patients. Knockdown of SMIM3 inhibited cell proliferation and cell cycle progression, and induced cell apoptosis in AML cells. The reduced SMIM3 expression significantly suppressed tumor growth in the xenograft mouse model. Western blot analysis showed downregulation of p-PI3K and p-AKT in SMIM3-knockdown AML cell lines. SMIM3 may also be associated with some PI3K-AKT and first-line targeted drugs. Conclusions: SMIM3 was highly expressed in adult AML, and such high-level expression of SMIM3 was associated with a poor prognosis in adult AML. Knockdown of SMIM3 inhibited the proliferation of AML through regulation of the PI3K-AKT signaling pathway. SMIM3 may serve as a potential prognostic marker and a therapeutic target for AML in the future.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype
    Yu Liu
    Yufei Chen
    Yajun Liu
    Mengya Li
    Yu Zhang
    Luyao Shi
    Lu Yang
    Tao Li
    Yafei Li
    Zhongxing Jiang
    Yanfang Liu
    Chong Wang
    Shujuan Wang
    Journal of Translational Medicine, 20
  • [2] Downregulation of GNA15 Inhibits Cell Proliferation via P38 MAPK Pathway and Correlates with Prognosis of Adult Acute Myeloid Leukemia With Normal Karyotype
    Li, Mengya
    Liu, Yu
    Liu, Yajun
    Yang, Lu
    Xu, Yan
    Wang, Weiqiong
    Jiang, Zhongxing
    Liu, Yanfang
    Wang, Shujuan
    Wang, Chong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Morusin Inhibits Human Osteosarcoma via the PI3K-AKT Signaling Pathway
    Zhang, Yong
    Weng, Qiuyan
    Chen, Jianming
    Han, Jinming
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2020, 21 (13) : 1402 - 1409
  • [4] Tumor suppressor miR-520a inhibits cell growth by negatively regulating PI3K/AKT signaling pathway in acute myeloid leukemia
    Xiao, Jing
    Wan, Fang
    Tian, Lin
    Li, Yao
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (07): : 729 - 738
  • [5] BmWARS inhibits BmNPV infection via the PI3K-Akt pathway
    Wang, Jinyang
    Ding, Xiangrui
    Jia, Kaifang
    Chen, Haiyu
    An, Guorong
    Zhao, Qiaoling
    Shen, Dongxu
    Qiu, Zhiyong
    Zhang, Xuelian
    Qian, Heying
    Xia, Dingguo
    BULLETIN OF ENTOMOLOGICAL RESEARCH, 2025,
  • [6] Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway
    Guo, Jiang-Rui
    Li, Wei
    Wu, Yong
    Wu, Lin-Qing
    Li, Xin
    Guo, Ya-Fei
    Zheng, Xiao-Hui
    Lian, Xiao-Lan
    Huang, Hui-Fang
    Chen, Yuan-Zhong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (09): : 3630 - 3644
  • [7] Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells
    Sansacar, Merve
    Sagir, Helin
    Akcok, Emel Basak Gencer
    MEDICAL ONCOLOGY, 2023, 41 (01)
  • [8] Plantamajoside Inhibits the Growth of Acute Myeloid Leukemia Cells by Modulating NF-κB and PI3K/AKT Signaling Pathways
    Zhou, Xiaolu
    Wang, Guochuan
    Wu, Qiongsheng
    Yang, Mei
    CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, 2022, 20 (03) : 513 - 519
  • [9] The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
    Nepstad, Ina
    Hatfield, Kimberley Joanne
    Gronningsaeter, Ida Sofie
    Reikvam, Hakon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [10] Downregulation of HDGF inhibits the tumorigenesis of bladder cancer cells by inactivating the PI3K-AKT signaling pathway
    Zhang, Cong
    Chang, Xiangping
    Chen, Dongshan
    Yang, Feilong
    Li, Zeyan
    Li, Dawei
    Yu, Nengwang
    Yan, Lei
    Liu, Hainan
    Xu, Zhonghua
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7909 - 7923